Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2021-01-14
2023-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The practice of mindfulness meditation has recently been included in the recommendations of the International League Against Epilepsy in order to alleviate anxiety or depression comorbid symptoms.
This study falls within this framework by targeting two aspects of the pathology.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Epilepsy, which results from the activity of hyperexcitable circuits, is also associated with a disorganization of the physiological brain networks. Studies in cognitive neuroscience in healthy subjects suggest that meditation induces lasting changes in the physiological networks of attention and default mode and could potentially compensate for dysfunctions of these networks in epileptic patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Therapeutic education group
The psychologist associated with the project takes care of the patient to receive a 1.5 hour therapeutic education interview ("control" group).
Therapeutic education
Patients will benefit from a 2-hour interview which will be conducted by the psychologist associated with the project.
The aim of this interview is to help patients better understand their disease in order to adopt the right behaviors on a daily basis. This session will inform patients about their disease, its origins, its treatment, the difficulties it causes and the means to remedy it. The objective of this session is to better understand and manage epilepsy and to enable patients to take an active part in the process of care and management of the disease.
No specific instructions will be given at the end of this interview.
Mindfulness meditation group
The psychologist associated with the project takes care of the patient to receive training in mindfulness meditation twice (1.5 hours) ("active" group)
Mindfulness meditation training
Patients will be able to benefit from mindfulness meditation training at the rate of 1h30 in the morning and 1h30 in the afternoon. During this training, patients will be invited to share with the psychologist their vision of mindfulness meditation and their expectations of this practice. The psychologist will then introduce what mindfulness is and how the sessions will take place. Several sessions guided by the psychologist will then be offered to the patient (body scan, focused attention, mindfulness movements...).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mindfulness meditation training
Patients will be able to benefit from mindfulness meditation training at the rate of 1h30 in the morning and 1h30 in the afternoon. During this training, patients will be invited to share with the psychologist their vision of mindfulness meditation and their expectations of this practice. The psychologist will then introduce what mindfulness is and how the sessions will take place. Several sessions guided by the psychologist will then be offered to the patient (body scan, focused attention, mindfulness movements...).
Therapeutic education
Patients will benefit from a 2-hour interview which will be conducted by the psychologist associated with the project.
The aim of this interview is to help patients better understand their disease in order to adopt the right behaviors on a daily basis. This session will inform patients about their disease, its origins, its treatment, the difficulties it causes and the means to remedy it. The objective of this session is to better understand and manage epilepsy and to enable patients to take an active part in the process of care and management of the disease.
No specific instructions will be given at the end of this interview.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients over 16 years of age;
* Epilepsy refractory to drug treatment according to the consensus criteria of the International League Against Epilepsy ;
* Affiliated with a health insurance plan;
* Free, informed and written consent signed by the patient, and parents for patients under the age of 18.
* For healthy subjects :
* Healthy subjects 16 years of age and older;
* Affiliated with a health insurance plan;
* Free, informed and written consent signed by the volunteer, or parents, for volunteers under the age of 18.
Exclusion Criteria
* Alcohol Addiction Disorders (assessed by the Mini-International Neuropsychiatric Interview (MINI) scale) ;
* Patients with psychogenic crises;
* Treatment with antidepressants;
* Simultaneous participation in other research that may interfere with the protocol;
* Persons of legal age subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.
* For healthy subjects :
* Psychiatric pathology and/or alcohol addiction disorders (evaluated by the MINI scale) ;
* Simultaneous participation in other research that may interfere with the protocol;
* Persons of legal age subject to legal protection (protection of justice, guardianship, trusteeship), persons deprived of liberty.
16 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratoire Traitement du Signal et de l'Image, INSERM UMR1099 Rennes
UNKNOWN
Centre Hospitalier Guillaume Régnier, RENNES
UNKNOWN
Rennes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isabelle MERLET, PhD
Role: STUDY_CHAIR
LTSI - INSERM UMR 1099
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire
Rennes, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anca NICA, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A02336-33
Identifier Type: OTHER
Identifier Source: secondary_id
35RC20_8848
Identifier Type: -
Identifier Source: org_study_id